Log in

TSE:NRINuvo Pharmaceuticals Stock Price, Forecast & News

C$0.75
-0.03 (-3.85 %)
(As of 07/8/2020 06:46 AM ET)
Add
Compare
Today's Range
C$0.75
Now: C$0.75
C$0.75
50-Day Range
C$0.70
MA: C$0.76
C$0.82
52-Week Range
C$0.28
Now: C$0.75
C$1.20
Volume1,000 shs
Average Volume20,214 shs
Market CapitalizationC$8.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-6736980

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$79.36 million
Cash FlowC$1.55 per share
Book ValueC$2.01 per share

Profitability

Miscellaneous

Employees97
Market CapC$8.54 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive NRI News and Ratings via Email

Sign-up to receive the latest news and ratings for NRI and its competitors with MarketBeat's FREE daily newsletter.

Nuvo Pharmaceuticals (TSE:NRI) Frequently Asked Questions

How has Nuvo Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Nuvo Pharmaceuticals' stock was trading at C$0.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NRI shares have decreased by 6.3% and is now trading at C$0.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Nuvo Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nuvo Pharmaceuticals.

When is Nuvo Pharmaceuticals' next earnings date?

Nuvo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Nuvo Pharmaceuticals.

How were Nuvo Pharmaceuticals' earnings last quarter?

Nuvo Pharmaceuticals Inc (TSE:NRI) posted its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported $0.16 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $24.36 million during the quarter. View Nuvo Pharmaceuticals' earnings history.

Has Nuvo Pharmaceuticals been receiving favorable news coverage?

Media stories about NRI stock have trended negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nuvo Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Nuvo Pharmaceuticals.

Who are some of Nuvo Pharmaceuticals' key competitors?

What other stocks do shareholders of Nuvo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvo Pharmaceuticals investors own include Avigilon (AVO), Spartan Energy (SPE), Aurora Cannabis (ACB), Allena Pharmaceuticals (ALNA), Bombardier, Inc. Class B (BBD.B), Cameco (CCO), Crescent Point Energy (CPG), First Quantum Minerals (FM), Genocea Biosciences (GNCA) and Kopin (KOPN).

Who are Nuvo Pharmaceuticals' key executives?

Nuvo Pharmaceuticals' management team includes the following people:
  • Mr. Robert Paul Harris, Exec. Chairman (Age 64)
  • Mr. Jesse F. Ledger, Pres & CEO
  • Ms. Mary-Jane E. Burkett CPA-CA, HBA, VP & CFO
  • Ms. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. Counsel
  • Mr. Calogero Lunetta MSc, VP of Manufacturing

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NRI."

How do I buy shares of Nuvo Pharmaceuticals?

Shares of NRI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Nuvo Pharmaceuticals' stock price today?

One share of NRI stock can currently be purchased for approximately C$0.75.

How big of a company is Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals has a market capitalization of C$8.54 million and generates C$79.36 million in revenue each year. Nuvo Pharmaceuticals employs 97 workers across the globe.

What is Nuvo Pharmaceuticals' official website?

The official website for Nuvo Pharmaceuticals is www.nuvopharmaceuticals.com.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-6736980.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.